$8.50
4.04% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US48669G1058
Symbol
KZIA

Kazia Therapeutics Ltd Sponsored ADR Stock price

$8.50
-2.93 25.63% 1M
+3.60 73.47% 6M
-0.35 3.95% YTD
-11.83 58.18% 1Y
-81.00 90.50% 3Y
-278.00 97.03% 5Y
-591.50 98.58% 10Y
-6,375.09 99.87% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.33 4.04%
ISIN
US48669G1058
Symbol
KZIA
Industry

Key metrics

Basic
Market capitalization
$9.1m
Enterprise Value
$8.5m
Net debt
positive
Cash
$2.0m
Shares outstanding
96.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.9 | 408.0
EV/Sales
5.6 | 381.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-46.4%
Return on Equity
267.3%
ROCE
-2,147.6%
ROIC
-593.8%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$1.5m | $22.3k
EBITDA
- | $4.7m
EBIT
$-19.5m | $-18.9m
Net Income
$-18.6m | $-1.7b
Free Cash Flow
$-7.6m
Growth (TTM | estimate)
Revenue
7,550.0% | -98.5%
EBITDA
- | 128.4%
EBIT
-55.3% | -6.9%
Net Income
-81.0% | -9,477.8%
Free Cash Flow
8.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | 21,071.1%
EBIT
-1,278.1%
Net
-1,212.9% | -7,505,074.6%
Free Cash Flow
-498.1%
More
EPS
$0.0
FCF per Share
$-0.1
Short interest
3.4%
Employees
13
Rev per Employee
$120.0k
Show more

Is Kazia Therapeutics Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

Buy
88%
Hold
13%

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1.53 1.53
7,550% 7,550%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.22 9.22
59% 59%
603%
- Research and Development Expense 11 11
65% 65%
740%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -20 -20
55% 55%
-1,277%
Net Profit -19 -19
81% 81%
-1,212%

In millions USD.

Don't miss a Thing! We will send you all news about Kazia Therapeutics Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral
PRNewsWire
12 days ago
SYDNEY , Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to an aggre...
Neutral
PRNewsWire
about one month ago
SYDNEY , July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to...
Neutral
PRNewsWire
2 months ago
SYDNEY , June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research that underscores the powerful potential of its lead...
More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office Australia
CEO John Friend
Employees 13
Founded 1994
Website www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today